Pilot Study of a Personalized Synthetic Long Peptide Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma

Trial Profile

Pilot Study of a Personalized Synthetic Long Peptide Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs Nivolumab (Primary) ; Synthetic vaccines (Primary) ; Poly ICLC; Rituximab
  • Indications Follicular lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Dec 2017 Planned End Date changed from 31 Jan 2027 to 30 Apr 2027.
    • 01 Dec 2017 Planned primary completion date changed from 31 Jul 2021 to 31 Oct 2021.
    • 01 Dec 2017 Planned initiation date changed from 1 Oct 2017 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top